Regen BioPharma Reports $59.1M Revenue for Q3 2025, Sees Significant Operating Loss

Regen BioPharma Inc. reported its financial results for the three and nine months ended June 30, 2025, revealing a net revenue of $59.1 million for the quarter, consistent with the same period in 2024. For the nine-month period, the company also reported net revenue of $177.2 million, slightly up from $177.1 million in the prior year. The revenue figures included $27.4 million from related parties, primarily from a licensing agreement with Zander Therapeutics, which remained unchanged year-over-year.

Operating expenses for the three months ended June 30, 2025, totaled $99.8 million, a significant decrease from $167.0 million in the same quarter of 2024. This reduction was largely due to a complete elimination of research and development expenses, which were $32.5 million in the prior year. General and administrative expenses increased by 86% to $30.7 million, while consulting and professional fees decreased by 51% to $46.6 million. The company reported a loss from operations of $40.8 million for the quarter, an improvement from a loss of $108.0 million in the same period last year.

For the nine-month period, total operating expenses were $392.7 million, down from $509.0 million in 2024. The decrease was attributed to lower research and development costs, which fell to zero from $120.2 million, while general and administrative expenses rose to $57.4 million from $38.3 million. The net loss for the nine months was $702.0 million, compared to a loss of $397.5 million in the previous year, primarily due to a significant derivative loss of $376.3 million recognized in 2025.

In terms of operational developments, Regen BioPharma's cash position at the end of the reporting period was $1,761, reflecting a slight increase from the previous year. The company reported a working capital deficit of approximately $5.8 million, which has raised concerns about its ability to continue as a going concern. Management indicated that the company is actively seeking additional funding through equity or debt offerings to support its operations and development plans.

Looking ahead, Regen BioPharma faces significant challenges, including the need for substantial cash resources to execute its business plans and the ongoing requirement to secure additional working capital. The company has incurred recurring losses and negative cash flows since its inception, leading to substantial doubt about its ability to continue operations without further financing. The management's outlook emphasizes the necessity of obtaining additional funding to sustain operations and advance its product development initiatives.